Prophylaxis for PONV: Why, Who, and How Literature Based Evidence and Recommendations

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Prophylaxis for PONV: Why, Who, and How Literature Based Evidence and Recommendations"

Transcription

1 Prophylaxis for PONV: Why, Who, and How Literature Based Evidence and Recommendations Robert M. Knapp, D.O., J.D. Postoperative nausea and vomiting (PONV) is a frequent source of patient distress as well as an expense for the institution. We cannot eliminate it at this time, but it is possible to lessen its incidence. Different anesthetic techniques are associated with different rates of occurrence. Various medications can raise or lower the incidence. In theory, this knowledge should lead to a rational strategy to minimize the occurrence of PONV. At this time, there are literally dozens of studies examining various aspects of PONV prophylaxis. Taken together, they appear to establish that 1) there is a rationale for PONV prophylaxis in certain patients who receive anesthesia, that 2) it is possible to define this group with a reasonable degree of certainty, and that 3) consistent and rational PONV prophylaxis will simultaneously maximize both cost efficiency and patient satisfaction. In reviewing this literature, please note the main results that underlie the therapeutic recommendations. The most important is that, no matter which drugs are chosen, the impact of any prophylactic drug regimen on PONV is slight. In fact, if you give prophylaxis randomly, the outcome will not be significantly different than if you had not given prophylaxis. It is only when you single out a group of patients more likely to have PONV than average that you begin to get results that are at least measurable. This should make it no surprise that, as prophylaxis, no drug is particularly effective. Finally, the serotonin antagonists have significant side effects and are far more effective at treating vomiting than preventing it. Determining their role in PONV requires a risk vs. benefit analysis.

2 Summary of Recommended Actions Consistent with Literature Based Evidence 1) Screen pre-op patients for PONV risk. Use these four factors in your screen: 1) Female, 2) Perioperative narcotic use, 3) Previous PONV, 4) Previous motion sickness. There are three groups of patients at risk: a) Those with any three factors b) Females who receive perioperative narcotics. c) Those with a history of previous PONV who receive perioperative narcotics. 2) Provide PONV prophylaxis to all patients who are at risk for PONV, consistent with indications and contraindications to the recommended drugs. 3) Use the following recommended drugs: A combination of one or more long acting agent (dexamethasone 4 mg IV, scopolamine transdermal patch) and one or more shorter acting agents (Metoclopramide mg IV, ephedrine mg IM). 4) Use serotonin antagonists (ondansetron [Zofran], granisetron [Kytril]) only after PONV starts and only after consideration of their side effects, because they are a much better treatment for PONV than a prophylactic. Treatment dosage for ondansetron appears to be 1-2 mg. IV. If a serotonin antagonist was given during surgery, do not give a repeat dosage in the PACU. 5) Tailor neostigmine dosages to clinical need at the time they are given. 6) Do not base a decision to use or not use nitrous oxide solely on concerns about PONV.

3 I. Should you use PONV prophylaxis? Issues: Is PONV prophylaxis cost effective? Does it increase patient satisfaction? If it is worth giving, who should get it?

4

5 1) Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology 92:958-67, This single study establishes a rational basis for administering PONV prophylaxis, and also a compelling reason for doing so. Prophylaxis is unequivocally shown to increase patient satisfaction and decrease overall institutional costs 1) when it is given to patients more at risk than average for PONV, and 2) when giving it is compared with not giving it. Notice that not giving prophylaxis to the correct group of patients costs more than giving it to that group. Also note that patient satisfaction was equivalent for all treated groups. The practical limitation of this study is that no method is given for identifying the group at high risk of developing PONV.

6 Conclusion: It is advantageous to the patient and to the institution to administer PONV prophylaxis. It should be used consistently in patients at risk for PONV. II. Can we predict which patients are at risk for PONV? Issues: Can we use a "risk factor" scoring system for predicting who is at risk for PONV? What are the limitations of such a system? What factors predict PONV? Is neostigmine a risk factor for PONV? Is nitrous oxide a risk factor for PONV?

7

8 2) What can be expected from risk scores for predicting postoperative nausea and vomiting? BritishJournalAnaesthesia 86:822-7, Factors indicating an increased risk of PONV do exist. Using several risk factors more accurately predicts PONV than using one or two. However, the limit of accuracy is reached at four to five factors. This limitation means that using more factors does not make the prediction of PONV any more accurate. In practical terms, you can use 4-5 factors to accurately say that a person has a 60-70% chance of getting PONV; but there is no number of factors that lets you accurately say that someone has a % chance of getting PONV. This means that you can say someone is a member of a group at high risk for getting PONV, but you can never say that person will definitely get PONV.

9

10 3) Prediction of PONV using a logistic regression model. BritishJounalAnaesthesia 76:347-51, There are four significant risk factors for getting PONV, as well as many more factors that do not predict risk. Notice the clinical confirmation of the limitations of the statistical model in the previous paper. In general, a high-risk individual is defined by having at least 3 of the following factors: female, previous PONV, administration of perioperative opioids, and a history of motion sickness. Perioperative opioids and either previous PONV or female sex also indicates a significant PONV risk.

11

12 4) Omitting antagonism of neuromuscular block: Effect on PONV and risk of residual paralysis. A systematic review. BritishJounalAnaesthesia 82:379-86,1999. Neostigmine can be a fifth PONV risk factor in dosages greater than two mg. However, not using it can pose a measurable and significant risk of clinically relevant muscle weakness for the patient.

13

14 5) Omitting nitrous oxide in general anaesthesia: Meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. BritishJounalAnaesthesia 76:186-93,1996. Nitrous oxide adds to the number of patients who have postoperative vomiting only if the baseline risk of vomiting is above average. The average risk groups experience no increase in PONV when nitrous oxide is used.

15 Conclusion: Using a 4 factor screen, the group of patients at higher than average risk for PONV can be identified. No greater number of factors need be used, and no individual can be predicted to have PONV with certainty. Under certain circumstances, both neostigmine and nitrous oxide can increase the incidence of PONV. III. How should ondansetron (Zofran), a serotonin antagonist, be used in the management of PONV? Issues: How effective is ondansetron at preventing PONV? What dosage should be given? What adverse effects accompany ondansetron? How effective is ondansetron at treating PONV? How effective is ondansetron when used for both prevention and treatment in the same patient?

16

17 6) Efficacy, dose-response, and safety of ondansetron in prevention of PONV. Anesthesiology 87: , Prophylactic ondansetron will reduce PONV, but it's effect is not impressive compared to its ability to treat established PONV. If 100 postoperative patients who are going to have PONV are given ondansetron during surgery, 20 will be kept from vomiting, 3 will have headaches who would not have, and 3 more will have elevated liver enzymes who would not have. For PONV prevention, 8 mg is the overall most effective dose, although 4 mg is almost as good. The prophylactic antiemetic effect of ondansetron is comparable to using a propofol infusion or omitting nitrous oxide. On the other hand, ondansetron is much more efficient when treating established PONV. In established PONV, 1 mg of ondansetron has as good an effect as 8 mg. This plus the adverse effect profile for ondansetron is cause to question the logic of using it as a PONV prophylactic.

18

19

20 7) A qualitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. Tramer MR, et al, BMJ, 314: , Ondansetron is effective as a treatment for PONV once it actually occurs. Of 100 postoperative patients who vomit, about 25 will stop. This number stays essentially the same whether 1mg, 4mg, or 8 mg is used.

21

22 8) Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: A randomized, double-blind, placebocontrolled multicenter trial. Kovac AL, et al, J Clin Anesthesia, 11: , If a postoperative patient vomits after getting 4 mg of prophylactic ondansetron in the OR, an additional 4 mg PACU treatment dose does no better than placebo to control the vomiting.

23 Conclusion: Under the best of circumstances, giving prophylactic ondansetron to all high risk patients reduces their PACU vomiting rate from the untreated average base rate of 40% down to 32%. This holds for a dose of 8 mg, with the decrease being 1% or 2% less for a 4 mg dose. Also, to achieve the full 20% reduction, one must accept a 6% incidence of elevated liver enzymes and headaches as well as cautions on use related to abdominal surgery. On the other hand, without prophylaxis, and using as little as 1 mg of ondansetron in the PACU, the 40% base rate can be decreased to 30%. In summary, the use of high-dose/or/prophylactic ondansetron, as opposed to low-dose/pacu/treatment ondansetron, increases the chance of adverse effect with no improvement in outcome. In addition, giving ondansetron in the OR should actually block its further use in the PACU. This is because drug exposure, and presumably side effect incidence, increases with the dual exposure with no increase in therapeutic response. IV. Are drugs other than ondansetron useful in the management of PONV? Issues: Which drugs have comparable effect? What is their dosage and the duration of their effect? Should they be used singly or in combination?

24

25 9) A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. Fortney, et al, AnesthesiaAnalgesia, 86: , Three IV drug regimens were given prophylactically to reduce PONV: Droperidol 1.25 mg, droperidol mg, and ondansetron 4 mg. Droperidol 1.25 mg was the most effective in reducing emesis in the first two hours and nausea for the first 24 hours postop. All three regimens were better than placebo. The incidence of headache was significantly higher with ondansetron than with droperidol, but otherwise the incidence of adverse events was the same for both drugs. Specifically there was no difference in the incidence of sedation, anxiety, or hypotension. Opioid analgesics were needed by a smaller percentage of the droperidol patients than the ondansetron. This may or may not be related to the lower PONV incidence seen in the droperidol 1.25 mg group.

26

27 10) Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing PONV: A meta-analysis. AnesthesiaAnalgesia 88:1370-9, Droperidol and ondansetron are equally effective in preventing postoperative nausea and vomiting in adults. They are significantly more effective than metoclopramide. The overall risk of adverse effects was the same for all three, except for an increased risk of headache for ondansetron as opposed to droperidol. As long as droperidol is used in doses smaller than 2.5 mg, the CNS side effects of the three drugs are similar.

28

29 11) Dexamethasone for the prevention of PONV: A quantitative systematic review. AnesthesiaAnalgesia 90:186-94, Dexamethasone given as PONV prophylaxis is as efficacious as 8 mg of ondansetron. It is different in that its time to peak efficacy is several hours and its duration of action is up to 24 hours. Significant side effects were not reported. The issues of wound infection, wound dehiscence, and adrenal suppression were not addressed. It may be significant that the amounts used in these studies, 8-10 mg, are routinely used in ENT and oral surgery without encountering these complications.

30

31 12) Prospective randomized, double-blind comparative study of dexamethasone, ondansetron, and ondansetron plus dexamethasone as prophylactic antiemetic therapy in patients undergoing day-case gynaecological surgery. BritishJournalAnaesthesia 87:588-92, The combination of ondansetron and dexamethasone was more effective than the individual drugs in the first three hours after surgery, but not thereafter. This suggests the two drugs given together have an additive effect. It also supports the addition of a rapid onset, short acting agent to the slower onset, longer acting dexamethasone.

32

33 13) The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: A dose ranging study. AnesthesiaAnalgesia 91:1404-7, Dexamethasone is effective for PONV in a dose-related manner. It is fully effective at doses of 5 mg and above, and less than fully effective at doses of 2.5 mg and below.

34

35 14) Efficacy of ephedrine in the prevention of PONV. AnesthesiaAnalgesia 72:58-61, Intramuscular ephedrine has prophylactic efficacy against PONV. The effect is significantly greater than placebo and similar to IM droperidol. Sedation scores were significantly lower with ephedrine than with either droperidol or placebo.

36

37 15) Intramuscular ephedrine reduces emesis during the first three hours after abdominal hysterectomy. ActaAnesthesiolScand 44: , Intramuscular ephedrine was effective during the first three hours after surgery, but not later. There was no difference in pulse or blood pressure between IM ephedrine and placebo. The ephedrine patients were more awake during the first three hours.

38

39 16) The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: A quantitative review. AnesthesiaAnalgesia 95:133-43, Transdermal scopolamine is as effective as ondansetron (Zofran) in preventing PONV. This is true throughout the 24-hour postoperative period. Neither the type of anesthesia (balanced, inhaled, or neuraxial) nor the timing of the application (night before, immediate pre-op, or intra-op) affected the efficacy. Incidence of side effects was about 15-20%.

40 Conclusion: Dexamethasone, droperidol, metoclopramide, IM ephedrine, and transdermal scopolamine are comparable to ondansetron for PONV prophylaxis. Dexamethasone and transdermal scopolamine have a relatively long duration of action and a longer time to onset than the other drugs. There is no contraindication currently known to multidrug prophylaxis, and there are indications that it is preferable to single drug therapy. Droperidol may be unavailable due to FDA action.

41 Recommended actions for PONV prophylaxis: Screen all patients for PONV risk. If a patient is in the group at increased risk, provide two or more prophylactic drugs to which the patient has no contraindications. One of these should be dexamethasone 4 mg and/or a transdermal scopolamine patch. In addition, ephedrine mg IM, and metoclopramide mg IV should be considered. Use a serotonin antagonist only to treat PONV as it occurs. If using ondansetron, give 1-2 mg IV. Tailor neostigmine dosage to the clinical need at the time given. Do not give too much weight to PONV risk when deciding whether or not to use nitrous oxide. 4.2 March 27, 2003

Can we predict postoperative nausea and vomiting (PONV)?- A study of three different scoring systems. Tidsskr Nor Lægeforen 2000;120:2423-6

Can we predict postoperative nausea and vomiting (PONV)?- A study of three different scoring systems. Tidsskr Nor Lægeforen 2000;120:2423-6 Can we predict postoperative nausea and vomiting (PONV)?- A study of three different scoring systems. Tidsskr Nor Lægeforen 2000;120:2423-6 Tropé A, Ræder JC. Background: In order to pick out patients

More information

Measure #430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination Therapy National Quality Strategy Domain: Patient Safety

Measure #430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination Therapy National Quality Strategy Domain: Patient Safety Measure #430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination Therapy National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION:

More information

Postoperative nausea and vomiting (PONV) is a. Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting

Postoperative nausea and vomiting (PONV) is a. Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting Ambulatory Anesthesiology Section Editor: Peter S. A. Glass Special Article Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting Tong J. Gan, MD* Tricia

More information

ROYAL HOSPITAL FOR WOMEN

ROYAL HOSPITAL FOR WOMEN NEURAXIAL (intrathecal and/or epidural) OPIOID ANALGESIA This LOP is developed to guide clinical practice at the Royal Hospital for Women. Individual patient circumstances may mean that practice diverges

More information

Lidocaine Infusion for Perioperative Pain Management. Marley Linder, PharmD Matt McEvoy, MD

Lidocaine Infusion for Perioperative Pain Management. Marley Linder, PharmD Matt McEvoy, MD Lidocaine Infusion for Perioperative Pain Management Marley Linder, PharmD Matt McEvoy, MD Perioperative Surgical Home: PCS Shared Goals Improved Outcomes (pain, PONV, LOS, SSI) Improve Throughput (Clinic

More information

PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LAPAROSCOPIC BARIATRIC SURGERY

PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LAPAROSCOPIC BARIATRIC SURGERY PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LAPAROSCOPIC BARIATRIC SURGERY - Granisetron Alone vs Granisetron Combined with Dexamethasone/Droperidol - * AND PATRICK J OREGAN

More information

The Impact of Regional Anesthesia on Perioperative Outcomes By Dr. David Nelson

The Impact of Regional Anesthesia on Perioperative Outcomes By Dr. David Nelson The Impact of Regional Anesthesia on Perioperative Outcomes By Dr. David Nelson As a private practice anesthesiologist, I am often asked: What are the potential benefits of regional anesthesia (RA)? My

More information

In the general surgical population, the risk of postoperative

In the general surgical population, the risk of postoperative Comparison of Inhalation of Isopropyl Alcohol vs Promethazine in the Treatment of Postoperative Nausea and Vomiting (PONV) in Patients Identified as at High Risk for Developing PONV Joseph Pellegrini,

More information

HOW TO CITE THIS ARTICLE:

HOW TO CITE THIS ARTICLE: PROSPECTIVE, RANDOMIZED, DOUBLE BLIND STUDY TO COMPARE THE EFFICACY AND SAFETY OF GRANISETRON VERSUS ONDANSETRON IN PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING ELECTIVE LAPAROSCOPIC

More information

Texas Medicaid/CHIP Vendor Drug Program Drug Utilization Criteria For Outpatient Use Guidelines

Texas Medicaid/CHIP Vendor Drug Program Drug Utilization Criteria For Outpatient Use Guidelines About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information

More information

Postoperative nausea and vomiting (PONV) is

Postoperative nausea and vomiting (PONV) is Prophylactic Isopropyl Alcohol Inhalation and Intravenous Ondansetron Versus Ondansetron Alone in the Prevention of Postoperative Nausea and Vomiting in High-Risk Patients LT Kennett D. Radford, CRNA,

More information

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:

More information

A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results

A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results September 22, 2015 Forward-Looking Statements This presentation contains "forward-looking statements" as defined

More information

Perioperative Management of Patients with Obstructive Sleep Apnea. Kalpesh Ganatra,MD Diplomate, American Board of Sleep Medicine

Perioperative Management of Patients with Obstructive Sleep Apnea. Kalpesh Ganatra,MD Diplomate, American Board of Sleep Medicine Perioperative Management of Patients with Obstructive Sleep Apnea Kalpesh Ganatra,MD Diplomate, American Board of Sleep Medicine Disclosures. This activity is supported by an education grant from Trivalley

More information

Acute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC

Acute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC Acute Pain Management in the Opioid Dependent Patient Maripat Welz-Bosna MSN, CRNP-BC Relieving Pain in America (IOM) More then 116 Million Americans have pain the persists for weeks to years $560-635

More information

Postoperative nausea and vomiting (PONV) Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea

Postoperative nausea and vomiting (PONV) Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea LT Anthony W. Winston, CRNA, MS, NC, USN Bethesda, Maryland LT Robert S. Rinehart, CRNA, MS, NC,

More information

Associate Professor, Department of Anaesthesia, Government Medical College, Telangana. 3

Associate Professor, Department of Anaesthesia, Government Medical College, Telangana. 3 RANDOMIZED DOUBLE BLIND STUDY COMPARING ONDANSETRON, PALONOSETRON & GRANISETRON TO PREVENT POST OPERATIVE NAUSEA & VOMITING AFTER LAPAROSCOPIC SURGERIES UNDER GENERAL ANAESTHESIA G. Rajendra 1, P. V. Shiva

More information

AQI QCDR Measure Specification

AQI QCDR Measure Specification AQI QCDR Measure Specification Year 2015 Anesthesia Quality Institute Updated 4/27/15 [Type text] Contents ASA #6: Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

PRACTICE Guidelines are systematically developed recommendations

PRACTICE Guidelines are systematically developed recommendations Copyright by the American Society of Anesthesiologists. Unauthorized reproduction of this article is prohibited. Practice Guidelines for Postanesthetic Care An Updated

More information

Post Operative Nausea & Vomiting Use of Anti Emetic Agents in Anaesthesia

Post Operative Nausea & Vomiting Use of Anti Emetic Agents in Anaesthesia 2012 Scottish Universities Medical Journal, Dundee Published online: Feb 2012 Vol 1 Issue 1: page 89-97 Rother C Post-Operative Nausea & Vomiting use of anti-emetic agents in anaesthesia Post Operative

More information

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline

More information

Conflict of Interest. Learning Objectives. The Link Between Acute and Chronic Pain. None

Conflict of Interest. Learning Objectives. The Link Between Acute and Chronic Pain. None The Link Between Acute and Chronic Pain James P. Rathmell, M.D. Chief, Division of Pain Medicine Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Associate Professor

More information

Enhanced Recovery Initiative

Enhanced Recovery Initiative Enhanced Recovery Initiative On February 14, 2012, the Colon and Rectal Surgery Service at St Joseph Mercy Hospital, Ann Arbor, launched the Enhanced Recovery Initiative, a collection of evidence-based

More information

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada

More information

The Outpatient Knee Replacement Program at Orlando Orthopaedic Center. Jeffrey P. Rosen, MD

The Outpatient Knee Replacement Program at Orlando Orthopaedic Center. Jeffrey P. Rosen, MD The Outpatient Knee Replacement Program at Orlando Orthopaedic Center Jeffrey P. Rosen, MD Anesthesia Pain Management Post-Op / Discharge Protocols The Orlando Orthopaedic Center Joint Replacement Team

More information

A Patient s Guide to PAIN MANAGEMENT. After Surgery

A Patient s Guide to PAIN MANAGEMENT. After Surgery A Patient s Guide to PAIN MANAGEMENT After Surgery C o m p a s s i o n a n d C o m m i t m e n t A Patient s Guide to Pain Management After Surgery If you re facing an upcoming surgery, it s natural to

More information

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration

More information

Guidelines for the Management of PONV

Guidelines for the Management of PONV Guidelines for the Management of PONV TONG J. GAN, MB Professor and Vice Chair for Clinical Research Medical Director, Clinical Anesthesia Research Endeavor (CARE) Department of Anesthesiology Duke University

More information

Delayed emesis: moderately emetogenic chemotherapy

Delayed emesis: moderately emetogenic chemotherapy Support Care Cancer (2005) 13:104 108 DOI 10.1007/s00520-004-0700-8 R E V I E W A R T I C L E Fausto Roila David Warr Rebecca A. Clark-Snow Maurizio Tonato Richard J. Gralla Lawrence H. Einhorn Jorn Herrstedt

More information

Guidelines for the Practice of Anesthesia in Norway

Guidelines for the Practice of Anesthesia in Norway Guidelines for the Practice of Anesthesia in Norway History 1991 1st version 1994 1st revision 1998 2nd revision 2005 3rd revision on 19.03.05 by NAF (The Norwegian Society of Anesthesiology) 1 Table of

More information

VA SAN DIEGO HEALTHCARE SYSTEM MEMORANDUM 118-28 SAN DIEGO, CA

VA SAN DIEGO HEALTHCARE SYSTEM MEMORANDUM 118-28 SAN DIEGO, CA GUIDELINES FOR PATIENT-CONTROLLED ANALGESIA (PCA) AND PATIENT- CONTROLLED EPIDURAL ANALGESIA (PCEA) FOR ACUTE PAIN MANAGEMENT 1. PURPOSE: To assure the safe and effective use of patient controlled analgesia

More information

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9 Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer

More information

Chemotherapy Induced Nausea & Vomiting

Chemotherapy Induced Nausea & Vomiting Chemotherapy Induced Nausea & Vomiting A Nurse s Perspective Michael Flynn MSc, PG Cert, RGN Chemotherapy Nurse Consultant Guy s and St Thomas NHS Foundation Trust Guy s and St Thomas NHS Foundation Trust

More information

Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults

Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults Protocol Code Tumour group Physician Contact SCNAUSEA SUPPORTIVE CARE Dr. Paul Hoskins ELIGIBILITY Adults receiving

More information

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

Emergency Room Treatment of Psychosis

Emergency Room Treatment of Psychosis OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

More information

Anterograde amnesic effects of pethidine, hyoscine and diazepam in adults

Anterograde amnesic effects of pethidine, hyoscine and diazepam in adults Br. J. Pharmac. (1972), 44, 14-144. Anterograde amnesic effects of pethidine, hyoscine and diazepam in adults J. W. DUNDEE Department of Anaesthetics, The Queen's University of Belfast, Northern Ireland

More information

ANWICU knowledge

ANWICU knowledge ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted

More information

Update and Review of Medication Assisted Treatments

Update and Review of Medication Assisted Treatments Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment

More information

NE W! To reduce the frequency and intensity of migra i n es R e c o m m e n d M I G R E L I E F

NE W! To reduce the frequency and intensity of migra i n es R e c o m m e n d M I G R E L I E F NE W! NE W! To reduce the frequency and intensity of migra i n es...... R e c o m m e n d M I G R E L I E F Most migraine patients do not receive preventive therapy Only 3% to 5% of migraine patients in

More information

TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSE REPAIR.

TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSE REPAIR. TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSE REPAIR. Spanish full text SUMMARY Introduction: Pelvic organ prolapse (POP) is characterised by the descent or herniation of the uterus, vaginal vault, bladder

More information

Substance Abuse Treatment. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence

Substance Abuse Treatment. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence Spring 2007 Volume 6 Issue 1 ADVISORY News for the Treatment Field Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence What is naltrexone for extendedrelease injectable

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Efficacy and Safety of Sublingual Sufentanil for the Management of Acute Pain Following Bunionectomy

Efficacy and Safety of Sublingual Sufentanil for the Management of Acute Pain Following Bunionectomy Efficacy and Safety of Sublingual Sufentanil for the Management of Acute Pain Following Bunionectomy Neil Singla, MD 1, Derek Muse, MD 2, Karen DiDonato, MSN, RN 3 and Pamela Palmer, MD, PhD 3 1 Lotus

More information

IV Oxycodone: An alternative to IV Morphine for post-operative PCA use?

IV Oxycodone: An alternative to IV Morphine for post-operative PCA use? IV Oxycodone: An alternative to IV Morphine for post-operative PCA use? Damien Polioudakis Anaesthetic Registrar 25-09-2008 Acknowledgements Spiro Raftopoulos Hospital Specialist Representative - VIC What

More information

There seem to be inconsistencies regarding diabetic management in

There seem to be inconsistencies regarding diabetic management in Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional

More information

Feline Anesthesia Richard M. Bednarski, DVM, MSc The Ohio State University College of Veterinary Medicine Current Issues in Feline Anesthesia

Feline Anesthesia Richard M. Bednarski, DVM, MSc The Ohio State University College of Veterinary Medicine Current Issues in Feline Anesthesia Feline Anesthesia Richard M. Bednarski, DVM, MSc The Ohio State University College of Veterinary Medicine Current Issues in Feline Anesthesia Chemical Restraint Protocols Trap, Neuter, Release Anesthetic

More information

Indicated for flu treatment for ages 2 weeks and older

Indicated for flu treatment for ages 2 weeks and older DOSAGE AND ADMINISTRATION IN ADULT AND PEDIATRIC PATIENTS Please see Important Safety Information on pages 6 8. Indicated for flu treatment for ages 2 weeks and older Available in 30-mg, 45-mg, and 75-mg

More information

CONTRAINDICATIONS None. (4) OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% Initial U.S. Approval: 2014

CONTRAINDICATIONS None. (4) OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMIDRIA safely and effectively. See full prescribing information for OMIDRIA. OMIDRIA (phenylephrine

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007

More information

New Zealand Data Sheet

New Zealand Data Sheet MESTINON Pyridostigmine bromide Presentation New Zealand Data Sheet 60mg tablet: round, flat-faced, white tablets engraved "Mestinon 60" on outer perimeter and "V" in the centre, with a quadrisect score

More information

Pediatric Anesthesia/Pediatric Cardiac Anesthesia/ Pain Management Elective

Pediatric Anesthesia/Pediatric Cardiac Anesthesia/ Pain Management Elective Pediatric Anesthesia/Pediatric Cardiac Anesthesia/ Pain Management Elective Introduction: This elective may be undertaken as a full-time elective in pediatric anesthesia, pediatric cardiac anesthesia,

More information

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

RGN JOY LAUDE WATFORD GENERAL HOSPITAL, ENGLAND

RGN JOY LAUDE WATFORD GENERAL HOSPITAL, ENGLAND RGN JOY LAUDE WATFORD GENERAL HOSPITAL, ENGLAND Monitor patient on the ward to detect trends in vital signs and to manage accordingly To recognise deteriorating trends and request relevant medical/out

More information

Homma A, Imai Y, Tago H, Asada T, et al. Dement Geriatr Cogn Disord. 2009;27(3):232-9. Epub 2009 Feb 25.

Homma A, Imai Y, Tago H, Asada T, et al. Dement Geriatr Cogn Disord. 2009;27(3):232-9. Epub 2009 Feb 25. ALZIL (Donepezil) Available as tablets: 5 mg, 10 mg (1) Indications (for elderly): symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer s type (2) Recent trials: Abstract

More information

CEDAC FINAL RECOMMENDATION

CEDAC FINAL RECOMMENDATION CEDAC FINAL RECOMMENDATION CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A, FREE FROM COMPLEXING PROTEINS (Xeomin Merz Pharma Canada Ltd.) Indication: Post-stroke Spasticity Recommendation: The Canadian Expert

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Last Updated: Version 4.3a NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Voluntary Only The Joint Commission - Retired Measure Set: Surgical Care

More information

Bupivacaine liposomal injection was recently

Bupivacaine liposomal injection was recently Hosp Pharm 214;49(6):539 543 214 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 1.131/hpj496-539 Original Article Bupivacaine Liposomal Versus Bupivacaine: Comparative Review John Noviasky,

More information

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline

More information

Nucala. (mepolizumab) New Product Slideshow

Nucala. (mepolizumab) New Product Slideshow Nucala (mepolizumab) New Product Slideshow Introduction Brand name: Nucala Generic name: Mepolizumab Pharmacological class: Interleukin-5 antagonist Strength and Formulation: 100mg per vial; lyophilized

More information

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped

More information

Medications for Alcohol and Opioid Use Disorders

Medications for Alcohol and Opioid Use Disorders Medications for Alcohol and Opioid Use Disorders Andrew J. Saxon, M.D. Center of Excellence in Substance Abuse Treatment and Education (CESATE) VA Puget Sound Health Care System Alcohol Pharmacotherapy

More information

Emergency and inpatient treatment of migraine: An American Headache Society

Emergency and inpatient treatment of migraine: An American Headache Society Emergency and inpatient treatment of migraine: An American Headache Society survey. The objective of this study was to determine the practice preferences of AHS members for acute migraine treatment in

More information

Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions

Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions Table of Contents: Overview... Professional Services... 2 Services... 4 Overview Chemotherapy

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

CH CONSCIOUS SEDATION

CH CONSCIOUS SEDATION Summary: CH CONSCIOUS SEDATION It is the policy of Carondelet Health that moderate conscious sedation of patients will be undertaken with appropriate evaluation and monitoring. Effective Date: 9/4/04 Revision

More information

Systematic Review of Treatment for Alcohol Dependence

Systematic Review of Treatment for Alcohol Dependence Systematic Review of Treatment for Alcohol Dependence ALCOHOL ARCUATE NUCLEUS in Hypothalamus, pituitary Beta-endorphin Dynorphin Kappa receptor Nucleus Enkephalins accumbens Delta receptor (+) Mu receptor

More information

Passionate concerns about welfare and ethics have created an environment where discussions about

Passionate concerns about welfare and ethics have created an environment where discussions about M e d i c a t i o n s P A I N M A N A G E M E N T Lysa Pam Posner, DVM, Diplomate ACVA North Carolina State University Analgesia for Declaw Patients Onychectomy in cats is controversial both within and

More information

11. CANCER PAIN AND PALLIATION. Jennifer Reifel, M.D.

11. CANCER PAIN AND PALLIATION. Jennifer Reifel, M.D. 11. CANCER PAIN AND PALLIATION Jennifer Reifel, M.D. While supportive care was not one of the original clinical areas selected for the development of quality indicators, the Oncology and HIV Panel felt

More information

Postoperative nausea and vomiting, defined as nausea

Postoperative nausea and vomiting, defined as nausea SOGC CLINICAL PRACTICE GUIDELINE SOGC CLINICAL PRACTICE GUIDELINE No. 209, July 2008 Guideline for the Management of Postoperative Nausea and Vomiting This guideline has been approved by Executive and

More information

ANESTHESIA FOR LAPAROSCOPIC CHOLECYSTECTOMY: COMPARATIVE EVALUATION OF

ANESTHESIA FOR LAPAROSCOPIC CHOLECYSTECTOMY: COMPARATIVE EVALUATION OF ANESTHESIA FOR LAPAROSCOPIC CHOLECYSTECTOMY: COMPARATIVE EVALUATION OF - Desflurane/Sevoflurane vs. Propofol - GULCAN ERK *, GULAY ERDOGAN *, FAZILET SAHIN *, VILDAN TASPINAR * AND BAYAZIT DIKMEN * Summary:

More information

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR DENTAL MEDICINE

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR DENTAL MEDICINE DECEMBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Gingivitis

More information

Comparison/Control Groups. Mary Foulkes, PhD Johns Hopkins University

Comparison/Control Groups. Mary Foulkes, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Patient-controlled analgesia (PCA) is commonly

Patient-controlled analgesia (PCA) is commonly Patient-Controlled Analgesia Jeffrey A. Grass, MD, MMM Department of Anesthesiology, Western Pennsylvania Hospital and Allegheny General Hospital, Pittsburgh, Pennsylvania One of the most common methods

More information

9/16/2010. Contact Information. Objectives. Analgesic Ketamine (Ketalar )

9/16/2010. Contact Information. Objectives. Analgesic Ketamine (Ketalar ) Analgesic Ketamine (Ketalar )..the long and winding road to clinical practice Contact Information Lois Pizzi BSN, RN-BC Inpatient Pain Management Clinician UPMC Presbyterian Shadyside pizzilj@upmc.edu

More information

Rotation Specific Guidelines CCFP - EM Residency Program

Rotation Specific Guidelines CCFP - EM Residency Program Rotation Specific Guidelines CCFP - EM Residency Program ANAESTHESIA To utilize the relevant competencies contained within the CanMEDS-FM roles to develop anesthesia skills relevant to the emergency physician

More information

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract

More information

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour. Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,

More information

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone

More information

Postoperative Nausea and Vomiting after Inpatient and Outpatient Breast Surgery: Incidence and Effects of Midazolam

Postoperative Nausea and Vomiting after Inpatient and Outpatient Breast Surgery: Incidence and Effects of Midazolam Postoperative Nausea and Vomiting after Inpatient and Outpatient Breast Surgery: Incidence and Effects of Midazolam S. Wilson, H. Meyer, and K. Fecho Abstract Aims: Determine the incidence and identify

More information

Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA

Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings

More information

EMERGENCY CONTRACEPTION (EC)

EMERGENCY CONTRACEPTION (EC) What is new: (EC). Ulipristal is now available over the counter in pharmacies free of charge without the need for a prescription. Evidence has emerged that starting hormonal contraception immediately after

More information

PRACTICE Guidelines are systematically developed recommendations

PRACTICE Guidelines are systematically developed recommendations for Acute Pain Management in the Perioperative Setting An Updated Report by the American Society of Anesthesiologists Task Force on Acute Pain Management PRACTICE Guidelines are systematically developed

More information

Pain Management for Labour & Delivery

Pain Management for Labour & Delivery Pain Management for Labour & Delivery Departments of Anesthesia, Obstetrics, and Obstetrical Nursing December 2008 This pamphlet has been prepared to provide you, members of your family, and others who

More information

National Clinical Programme in Surgery (NCPS) Care Pathway for the Management of Day Case Laparoscopic Cholecystectomy

National Clinical Programme in Surgery (NCPS) Care Pathway for the Management of Day Case Laparoscopic Cholecystectomy National Clinical Programme in Surgery (NCPS) Care Pathway for the Management of Day Case Consultant Surgeon DRAFT VERSION 0.5 090415 Table of Contents 1.0 Purpose... 3 2.0 Scope... 3 3.0 Responsibility...

More information

One Size Does NOT Fit All: Opioid Dose Range Orders

One Size Does NOT Fit All: Opioid Dose Range Orders One Size Does NOT Fit All: Opioid Dose Range Orders Chris Pasero, MS, RN-BC, FAAN El Dorado Hills, California Funding for this initiative was made possible (in part) by Providers Clinical Support System

More information

One Size Does NOT Fit All: Opioid Dose Range Orders

One Size Does NOT Fit All: Opioid Dose Range Orders One Size Does NOT Fit All: Opioid Dose Range Orders Chris Pasero, MS, RN-BC, FAAN El Dorado Hills, California Funding for this initiative was made possible (in part) by Providers Clinical Support System

More information

Center for Medicaid and State Operations/Survey and Certification Group

Center for Medicaid and State Operations/Survey and Certification Group DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-12-25 Baltimore, Maryland 21244-1850 Center for Medicaid and State Operations/Survey

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within

More information

What is an NNT? What is...? series Second edition Statistics. Supported by sanofi-aventis

What is an NNT? What is...? series Second edition Statistics. Supported by sanofi-aventis ...? series Second edition Statistics Supported by sanofi-aventis What is an NNT? Andrew Moore MA DPhil DSc CChem FRSC Senior Research Fellow, Pain Research and Nuffield Department of Anaesthetics, University

More information

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 40 mg, film-coated tablet B/30 (CIP code: 381 540-6) B/56 (CIP code: 381 541-2) B/90 (CIP code:

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

INTERSCALENE BLOCK AND OTHER ARTICLES ON ANESTHESIA FOR ARTHROSCOPIC SURGERY NOT QUALIFYING AS EVIDENCE

INTERSCALENE BLOCK AND OTHER ARTICLES ON ANESTHESIA FOR ARTHROSCOPIC SURGERY NOT QUALIFYING AS EVIDENCE INTERSCALENE BLOCK AND OTHER ARTICLES ON ANESTHESIA FOR ARTHROSCOPIC SURGERY NOT QUALIFYING AS EVIDENCE Hughes MS, Matava MJ, et al. Interscalene Brachial Plexus Block for Arthroscopic Shoulder Surgery.

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information